Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria F Mojica

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Current Drug Targets|October 2, 2015
B1-Metallo-β-Lactamases: Where Do We Stand?Maria F Mojica, Robert A Bonomo, Walter Fast
Current Opinion in Infectious Diseases|October 17, 2023
Treatment approaches for severe Stenotrophomonas maltophilia infectionsMaria F Mojica, Robert A Bonomo, David van Duin
The Lancet. Infectious Diseases|July 11, 2021
The urgent need for metallo-β-lactamase inhibitors: an unattended global threatMaria F Mojica, Maria-Agustina Rossi, Alejandro J Vila, et al.
The Lancet. Microbe|May 11, 2026
Treatment strategies for imipenemase-producing Gram-negative infections: lessons from JapanDaisuke Ono, Sohei Harada, Yoshikazu Ishii, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 8, 2025
How do I manage a patient with Stenotrophomonas maltophilia infection?Roberta Monardo, Maria F Mojica, Marco Ripa, et al.
Microbiology Spectrum|September 24, 2024
Cefepime-taniborbactam demonstrates potent <i>in vitro</i> activity vs <i>Enterobacterales</i> with <i>bla</i><sub>OXA-48</sub>Maria F Mojica, Elise T Zeiser, Scott A Becka, et al.
ACS Infectious Diseases|October 23, 2024
Frameshift Mutations in Genes Encoding PBP3 and PBP4 Trigger an Unusual, Extreme β-Lactam Resistance Phenotype in <i>Burkholderia multivorans</i>Maria F Mojica, Michiyoshi Nukaga, Scott A Becka, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 29, 2023
Association of COVID-19 coinfection with increased mortality among patients with <i>Pseudomonas aeruginosa</i> bloodstream infection in the Veterans Health Administration systemLeila S Hojat, Brigid M Wilson, Federico Perez, et al.
Microbiology Spectrum|December 23, 2025
Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i><sub>OXA-48</sub>Maria F Mojica, Elise T Zeiser, Scott A Becka, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Examining the activity of cefepime-taniborbactam against <i>Burkholderia cepacia</i> complex and <i>Burkholderia gladioli</i> isolated from cystic fibrosis patients in the United StatesMaria F Mojica, Elise T Zeiser, Scott A Becka, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Current Drug Targets|October 2, 2015
B1-Metallo-β-Lactamases: Where Do We Stand?Maria F Mojica, Robert A Bonomo, Walter Fast
Current Opinion in Infectious Diseases|October 17, 2023
Treatment approaches for severe Stenotrophomonas maltophilia infectionsMaria F Mojica, Robert A Bonomo, David van Duin
The Lancet. Infectious Diseases|July 11, 2021
The urgent need for metallo-β-lactamase inhibitors: an unattended global threatMaria F Mojica, Maria-Agustina Rossi, Alejandro J Vila, et al.
The Lancet. Microbe|May 11, 2026
Treatment strategies for imipenemase-producing Gram-negative infections: lessons from JapanDaisuke Ono, Sohei Harada, Yoshikazu Ishii, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 8, 2025
How do I manage a patient with Stenotrophomonas maltophilia infection?Roberta Monardo, Maria F Mojica, Marco Ripa, et al.
Microbiology Spectrum|September 24, 2024
Cefepime-taniborbactam demonstrates potent <i>in vitro</i> activity vs <i>Enterobacterales</i> with <i>bla</i><sub>OXA-48</sub>Maria F Mojica, Elise T Zeiser, Scott A Becka, et al.
ACS Infectious Diseases|October 23, 2024
Frameshift Mutations in Genes Encoding PBP3 and PBP4 Trigger an Unusual, Extreme β-Lactam Resistance Phenotype in <i>Burkholderia multivorans</i>Maria F Mojica, Michiyoshi Nukaga, Scott A Becka, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|December 29, 2023
Association of COVID-19 coinfection with increased mortality among patients with <i>Pseudomonas aeruginosa</i> bloodstream infection in the Veterans Health Administration systemLeila S Hojat, Brigid M Wilson, Federico Perez, et al.
Microbiology Spectrum|December 23, 2025
Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying <i>bla</i><sub>OXA-48</sub>Maria F Mojica, Elise T Zeiser, Scott A Becka, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Examining the activity of cefepime-taniborbactam against <i>Burkholderia cepacia</i> complex and <i>Burkholderia gladioli</i> isolated from cystic fibrosis patients in the United StatesMaria F Mojica, Elise T Zeiser, Scott A Becka, et al.
Pageof 5